HomeFileStructural heart disease

Structural heart disease

Comparison Between Leadless Pacemaker vs. Transvenous Pacemaker After Percutaneous Aortic Valve Replacement

Transcatheter aortic valve replacement (TAVR) has proven to be effective in treating severe aortic stenosis. The volume...

ENVISAGE-TAVI AF Trial: What Anticoagulant Should We Use?

Between 15% and 30% of patients undergoing TAVR present atrial fibrillation. Many of them have suffered ischemic...

Evolution at 1 Year for the PARTNER 3 Mitral Valve-in-Valve Study

At present, the structural failure of mitral bioprostheses due to their deterioration poses a significant challenge. While...

Edge-to-Edge Tricuspid Valve Repair 3-Year Follow Up

Tricuspid regurgitation (TR) is associated to fatigue and peripheral edema, and medical treatment with diuretics has a...

Should We Withdraw Anticoagulation Before TAVR?

Approximately one-third of patients undergoing transcatheter aortic valve replacement (TAVR) have atrial fibrillation and are on oral...

MATTERHORN: Edge-to-Edge Repair vs. Surgery for Secondary Mitral Valve Regurgitation

Frequently associated with hospitalization for cardiac failure and mortality, secondary mitral valve regurgitation (MR) is the most...

RESHAPE-HF2 Trial: Edge-to-Edge Repair in Secondary Mitral Valve Regurgitation vs. Complete Medical Treatment

Severe secondary Mitral Valve Regurgitation (MR) has been associated with increased hospitalization and mortality. Even though optimal...

¿What Should We Do About Significant Coronary Lesions in TAVR?

Aortic stenosis and coronary artery disease (CAD) share risk factors, which means significant lesions will coexist in...